The Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) is set to launch in Canada in November 2023. This new system, authorized by Health Canada, is designed for adults aged 18 and older who are living with diabetes. It features an extended wear time of up to 15.5 days, reducing the need for frequent sensor changes, which can be beneficial for those managing their diabetes.
The Dexcom G7 is noted for its accuracy and durability in monitoring glucose levels, making it a significant advancement in diabetes care technology. In addition to its commercial availability, the system will also be publicly reimbursed for eligible Canadians, allowing for wider access among those who require continuous glucose monitoring. This development is expected to enhance the quality of life for many Canadians affected by diabetes, providing them with more consistent monitoring and less hassle associated with regular sensor changes.
The introduction of the Dexcom G7 in Canada reflects a broader trend in diabetes technology, which is increasingly focusing on user-friendly devices that offer better integration with daily life. As Canadian healthcare systems continue to adapt to new technologies, products like the Dexcom G7 can potentially lead to improved health outcomes for diabetes patients nationwide.
Analyzed Canadian Outlets (2)
1 headline · wire copies grouped